Does Asymptomatic H. Pylori Need Treatment?

H. pylori infection - Source: Libre Pathology

A common bacterial infection is at the root of many gastrointestinal illnesses. Helicobacter pylori (H. pylori) are associated with inflammation of the stomach lining (gastritis), peptic ulcer disease, and gastric cancer (Malfertheiner et al., 2023).

H. pylori infection is common with an estimated colonization of less than 40% of people in developed countries and 90% in developing countries in pediatrics. (Ozbey and Hanafiah, 2017). However, these percentages are largely averaged, meaning that prevalence varies considerably by geography, age, and socioeconomic factors. Infection is believed to be acquired in childhood and is usually lifelong.

H. pylori are implicated with gastric cancer, a leading cause of cancer worldwide, with approximately 30,000 new cases in the U.S. in 2025 (American Cancer Society, 2025). Death rates from stomach cancer have declined partially due to the decrease in H. pylori infection.

If H.pylori is associated with an increase incidence of stomach cancer, then should screening and eradication of the bacterial infection be part of usual preventative care? This is a question that physicians, researchers, and patient groups are grappling with. The short answer is that broad screening is not a simple yes or no. What follows are the sides of the debate.

Currently, the American Gastroenterological Association (AGA) recommends H. pylori screening for those only at high risk for infection, including immigrants, families with a diagnosed H. pylori infection, and patients with a family history of gastric cancer (Shah et al., 2024).

The Case for Broad Screening and Eradication

Advocates of expanded screening argue that because H. pylori are prevalent and strongly linked to serious disease, that a "test and treat" strategy in the general population could prevent morbidity and mortality (Shah et al., 2024). The logic is straightforward: eradicating the infection before it causes damage interrupts the progression from chronic gastritis to peptic ulcer disease and, possibly, gastric cancer.

Evidence from population-level studies in high-incidence regions, particularly in East Asia, supports this view. Mass screening and eradication programs in countries like Japan and South Korea have been associated with reductions in gastric cancer rates (Hamashima, 2015; Choi, 2022). Researchers argue that waiting for symptoms to appear before testing may already be too late, as infection-related mucosal damage can be well underway before a patient ever experiences discomfort (Malfertheiner et al., 2023).

Furthermore, H. pylori eradication is possible. Standard treatment, which is typically a combination of antibiotics and a proton pump inhibitor over 10 to 14 days, is effective for the majority of patients (Aldhaleei, Wallace, & Harris, 2024; Fallone et al, 2016). From a public health standpoint, treating an asymptomatic but infected individual may be far less costly than managing a peptic ulcer or a gastric cancer diagnosis down the line.

The Case Against Broad Screening

Opponents of universal screening raise several concerns. First, not everyone infected with H. pylori will develop serious disease. The bacterium is a known Group 1 carcinogen due to its ability to induce genetic mutations, inflammation, and cellular damage. However, the majority of infected individuals will live their entire lives without developing gastric cancer or even a symptomatic ulcer. Treating a large population to prevent disease in a smaller subset raises questions of cost-effectiveness, which can vary depending on regional disease prevalence, particularly in healthcare systems with limited resources.

Second, antibiotic resistance is a growing global problem. H. pylori treatment relies on antibiotics such as clarithromycin and metronidazole, both of which are seeing rising resistance rates worldwide (Baj et al., 2020). Broad eradication campaigns could accelerate this trend, potentially undermining the effectiveness of these drugs for other serious infections. Exposing millions of asymptomatic individuals to antibiotic courses also carries the risk of side effects, including disruption of the broader gut microbiome, adverse effects, and antibiotic resistance (Olekhnovich, 2019).

Third, there are practical barriers to large-scale implementation. Screening requires access to reliable diagnostic tools, including urea breath or stool antigen tests. It also may require an upper endoscopy procedure and, importantly, a healthcare infrastructure capable of providing treatment which is needed when alarm symptoms such as ulcer disease and premalignant findings are clear. In communities where access to care is already limited, a universal screening mandate may be difficult to execute.

Who Should Be Screened?

Given these competing considerations, current guidance for screening takes a targeted approach. The AGA recommends prioritizing screening for individuals at elevated risk, including first-generation immigrants from high-incidence regions (such as East Asia, Eastern Europe, and Latin America), individuals with a first-degree relative with gastric cancer, and those with a personal or family history of H. pylori infection (Shah et al., 2024). Patients with peptic ulcer disease, unexplained iron deficiency anemia, or immune thrombocytopenic purpura (ITP) would fall under targeted screening.

Beyond these groups, clinicians are encouraged to use clinical judgment. Patients presenting persistent dyspepsia (discomfort in the upper abdomen) of an unclear cause are generally candidates for a "test and treat" strategy as well. This approach avoids unnecessary endoscopy while still addressing a common and treatable underlying cause (Aldhaleei, Wallace, & Harris, 2024).

What If You Test Positive With No Symptoms?

If a person is incidentally found to have H. pylori such as through testing prompted by a family history or an unrelated workup, the question of whether to treat becomes more nuanced. Most major gastroenterology societies, including the AGA and the European Helicobacter and Microbiota Study Group, lean toward recommending eradication even in asymptomatic individuals who test positive, on the grounds that the benefits of eradication outweigh the relatively modest risks of a short antibiotic course (Malfertheiner et al., 2023).

The key takeaway is if you know you have H. pylori, current evidence supports treating it, regardless of whether you have symptoms.

Conclusion

H. pylori is a remarkably common infection with the potential for serious long-term health consequences. The debate over universal screening reflects a broader tension in preventive medicine between population-level benefit and individual-level risk, resource allocation, and the unintended consequences of large-scale antibiotic use.

For now, the evidence supports a risk-stratified approach: screen those at elevated risk, treat those who test positive, and continue investing in research to better understand who is most likely to benefit from eradication. If you have concerns about your own risk, a conversation with your physician or gastroenterologist is a sensible next step.

References

American Cancer Society. Cancer Facts and Statistics (2025). Retrieved from https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2025-cancer-facts-figures.html

Baj J, Forma A, Sitarz M, Portincasa P, Garruti G, Krasowska D, Maciejewski R. Helicobacter pylori virulence factors — mechanisms of bacterial pathogenicity in the gastric microenvironment. Cells. 2021 Dec 25;10(1):27. doi: 10.3390/cells10010027. PMID: 33375694; PMCID: PMC7824444.

Choi IJ, et al. Current evidence for a paradigm shift in gastric cancer prevention from endoscopic screening to Helicobacter pylori eradication in Korea. Journal of Gastric Cancer. 2022;22(3):175-194. PMC9359887.

Fallone CA, Chiba N, van Zanten SV, et al. The Toronto Consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151(1):51–69.e14. doi: 10.1053/j.gastro.2016.04.006.

Hamashima C. Screening of gastric cancer in Asia. Best Practice & Research Clinical Gastroenterology. 2015;29:895–905. doi: 10.1016/j.bpg.2015.09.013. PMID: 26651251.

Olekhnovich, E. I., Manolov, A. I., Samoilov, A. E., Prianichnikov, N. A., Malakhova, M. V., Tyakht, A. V., … Ilina, E. N. (2019). Shifts in the human gut microbiota structure caused by quadruple Helicobacter pylori eradication therapy. Frontiers in Microbiology, 10, 1902. https://doi.org/10.3389/fmicb.2019.01902

Malfertheiner P, Camargo MC, El-Omar E, Liou JM, Peek R, Schulz C, Smith SI, Suerbaum S. Helicobacter pylori infection. Nat Rev Dis Primers. 2023 Apr 20;9(1):19. doi: 10.1038/s41572-023-00431-8. PMID: 37081005

Mitchell HM. Epidemiology of infection. In: Mobley HLT, Mendz GL, Hazell SL, editors. Helicobacter pylori: Physiology and Genetics. Washington (DC): ASM Press; 2001. Chapter 2. Available from: https://www.ncbi.nlm.nih.gov/books/NBK2421/

Aldhaleei WA, Wallace MB, Harris DM, Bi Y. H Helicobacter pylori: a concise review of the latest treatments against an old foe. Cleveland Clinic Journal of Medicine. 2024;91(8):481–490. doi: 10.3949/ccjm.91a.23088.

Ozbey G, Hanafiah A. Epidemiology, diagnosis, and risk factors of Helicobacter pylori infection in children. Euroasian J Hepatogastroenterol. 2017 Jan–Jun;7(1):34–39. doi: 10.5005/jp-journals-10018-1208. PMID: 29201769; PMCID: PMC5663771.

Shah SC, Wang AY, Wallace MB, Hwang JH. AGA Clinical Practice Update on Screening and Surveillance in Individuals at Increased Risk for Gastric Cancer in the United States: Expert Review. Gastroenterology. 2025 Feb;168(2):405–416.e1. doi: 10.1053/j.gastro.2024.11.001. Epub 2024 Dec 23. PMID: 39718517.

Assessed and Endorsed by the MedReport Medical Review Board